My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 271

    1.

    Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

    Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI.

    Ann Intern Med. 2000 Aug 15;133(4):263-74.PMID: 10929166 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.

    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.

    Ann Intern Med. 2001 May 1;134(9 Pt 1):737-45.PMID: 11329231 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.

    Walli R, Michl GM, Mühlbayer D, Brinkmann L, Goebel FD.

    Res Exp Med (Berl). 2000 Apr;199(5):253-62.PMID: 10815754 [PubMed - indexed for MEDLINE]Related articles

    4.

    Efficacy of troglitazone on body fat distribution in type 2 diabetes.

    Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K.

    Diabetes Care. 2000 Aug;23(8):1067-71.PMID: 10937499 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.

    Ann Intern Med. 1998 Feb 1;128(3):176-85.PMID: 9454525 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

    Schwartz S, Raskin P, Fonseca V, Graveline JF.

    N Engl J Med. 1998 Mar 26;338(13):861-6.PMID: 9516220 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.

    Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, Tajima N.

    Metabolism. 2001 Apr;50(4):414-7.PMID: 11288035 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of troglitazone on body fat distribution in type 2 diabetic patients.

    Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y.

    Diabetes Care. 1999 Jun;22(6):908-12.PMID: 10372240 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

    Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.

    Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H.

    Antivir Ther. 2003 Jun;8(3):199-207.PMID: 12924536 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.

    Clin Pharmacol Ther. 1997 Aug;62(2):194-202.PMID: 9284856 [PubMed - indexed for MEDLINE]Related articles

    12.

    Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.

    Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, Takahashi M, Hotta K, Kuriyama H, Kihara S, Ohuchi N, Nishimura T, Kishino BI, Ishikawa K, Kawamoto T, Tokunaga K, Nakagawa C, Mineo I, Watanabe F, Tarui S, Matsuzawa Y.

    Diabetes Res Clin Pract. 2001 Dec;54(3):181-90.PMID: 11689273 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

    Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM.

    Obes Res. 2002 Oct;10(10):1008-15. Erratum in: Obes Res. 2002 Nov;10(11):following table of contents.. PMID: 12376581 [PubMed - indexed for MEDLINE]Related articles

    14.

    Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.

    Yokoyama I, Yonekura K, Moritan T, Tateno M, Momose T, Ohtomo K, Inoue Y, Nagai R.

    J Nucl Med. 2001 Jul;42(7):1005-10.PMID: 11438619 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.

    Kumar S, Prange A, Schulze J, Lettis S, Barnett AH.

    Diabet Med. 1998 Sep;15(9):772-9.PMID: 9737807 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.

    Diabetes Care. 1996 Feb;19(2):151-6.PMID: 8718436 [PubMed - indexed for MEDLINE]Related articles

    17.

    The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.

    Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M.

    J Clin Endocrinol Metab. 2009 Apr;94(4):1137-44. Epub 2009 Jan 27.PMID: 19174500 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.

    Kelly IE, Han TS, Walsh K, Lean ME.

    Diabetes Care. 1999 Feb;22(2):288-93. Erratum in: Diabetes Care 1999 Mar;22(3):536. PMID: 10333947 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

    Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW.

    Diabetes. 1997 Mar;46(3):433-9.PMID: 9032099 [PubMed - indexed for MEDLINE]Related articles

    20.

    Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.

    Gómez-Pérez FJ, Aguilar-Salinas CA, Vázquez-Chávez C, Fanghänel-Salmón G, Gallegos-Martínez J, Gómez-Diaz RA, Salinas-Orozco S, Chavira-López IJ, Sánchez-Reyes L, Torres-Acosta EM, Tamez R, López A, Guillén LE, Cesarman G.

    Metabolism. 2002 Jan;51(1):44-51.PMID: 11782871 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity